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long-term medical costs. RESULTS: Using 30-day mor-
tality data from the Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coro-
nary Arteries (GUSTO) trial, the baseline analysis yielded
an ICER for t-PA of $24,882/QALY compared to SK.
The ICER was sensitive to the difference in reinfarction
rate (baseline 3.83%: 3% ICER $19,326: 6% ICER
$120,767) and mortality rate (baseline 6.3%: 6.7%
ICER $46,688: 7.2% ICER $197,850) of t-PA. CON-
CLUSION: t-PA is a cost-effective therapy for MI com-
pared to SK. In addition, despite using costs and utilities
from varied sources, and employing a simpler model the
findings support previously published results.
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OBJECTIVES: The medical device implantation tech-
niques via percutaneous aboard tend to substitute to sur-
gical techniques, in various cardio-vascular therapeutics.
However, prosthesis implantation is often accompanied
high implementation costs (linked to the device acquisi-
tion) which are difficult to justify to the decision-maker,
in a context of high financial constraint. METHOD:
Available clinical data show similarity of effectiveness
and complication rates between these two techniques.
Therefore, the economic appraisal consists in a cost mini-
mization approach. First, we modeled the two technique
protocols before costing each action (personnel, facili-
ties, . . . ) according to the internal costs of Grenoble
hospital. Moreover, we estimated the budgetary produc-
tivity of these two strategies using the French DRG classi-
fication system used to adjust the annual financial alloca-
tion of French public hospitals. RESULTS: Results show
the percutaneous technique (septal occluder Amplatzer®)
is dominant (1.5 times less expensive than surgery),
mainly by decreasing the hospital stay (two hospitaliza-
tion days instead of 12 days in the surgery strategy).
DRG system classification generates 1473 ISA (hospital
productivity index) for the percutaneous technique and
7556 ISA for invasive surgery. CONCLUSIONS: Com-
paring between cost-minimization technic using internal
costs and incremental budgetary impact using French
DRG classification, we conclude that the prosthesis im-
plantation via percutaneous aboard is economically dom-
inant (cheaper than invasive surgery) but 5 times less
contributive to annual budget allocation. Therefore in-
citation for the hospital decision-maker to use septal
occluders must come with the adaptation to new techno-
logies of financial public allocation using the DRG classi-
fication.
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OBJECTIVE: To assess medication compliance and pre-
dictors of compliance with HMG-CoA reductase inhibi-
tors for patients following a myocardial infarction (MI)
or other atherosclerotic event. METHODS: Patients were
identified from a managed care organization (MCO) da-
tabase who had an MI or other atherosclerotic event in
1997 or 1998 and were continuously enrolled in the
MCO for the year following the event. All patient records
were collected following guidelines for HEDIS reporting.
Pharmacy claims data review identified 216 patients who
had at least one prescription filled for a statin. A number
of compliance measures were calculated, including the
CMA, a continuous multiple-interval measure of medica-
tion availability. A multivariate linear regression of CMA
included the following independent variables: age, sex,
ICD-9 of admission, DRG of admission, statin prescribed,
medication days supply dispensed, number of unique
medications prescribed, number of unique chronic medi-
cations prescribed, and prescription drug copay amount.
RESULTS: The mean CMA was 0.820. Regression re-
sults (adjusted r-square 0.11) indicate that several factors
had potentially large impacts on CMA, but the estimates
were associated with large standard errors (age, gender,
ICD-9 of admission, DRG of admission, statin pre-
scribed). Four factors with estimates statistically signifi-
cantly different from zero are as follows (t-statistics in
parentheses): days supply (each 30-day increment) 0.116
(3.61), number of concomitant unique medications 0.009
(2.29), number of concomitant unique chronic medica-
tions 0.012 (1.83), copay (each $1) 0.007 (2.84). CON-
CLUSIONS: Compliance with statins was high in this
sample, but not ideal (1.0). Strategies for improving com-
pliance that may have merit include: providing patients
with 60 or 90-day supplies (rather than 30-day supplies),
controlling the number of other medications prescribed
and having lower patient copayments for these important
medications.
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OBJECTIVES: German hospitals receive the same reim-
bursement by the statutory health insurance for CABG
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surgery irrespective of whether or not a rethoracotomy,
which involves higher in-hospital costs, has to be per-
formed following hemorrhage. In order to evaluate the
in-hospital costs for CABG with and without rethoracot-
omy from the hospital perspective, a cost-analysis of
CABG surgery was performed. Furthermore, the cost-
effectiveness of prophylactic administration of the anti-
hemorrhagic agent aprotinin was investigated. METH-
ODS: The detailed resource utilization of 138 CABG
patients, 68 with rethoracotomy and 70 without, was
analysed based on sample of patient medical records
from 7 German hospitals. Resource costs were provided
by hospital administrations and supplemented by litera-
ture. The overall costs for both groups were then com-
bined with rethoracotomy rates in patients with and
without prophylactic administration of aprotinin derived
from a published meta-analysis of all relevant clinical tri-
als in open heart surgery. RESULTS: The total in-hospi-
tal costs per patient with CABG were on average DM
21,241 and increased to DM 31,326 for a CABG patient
requiring rethoracotomy. Besides the costs of the rethora-
cotomy, the costs of intensive care were the main cost
driver in patients with rethoracotomy. The meta-analysis
showed with statistical significance that aprotinin can re-
duce the rethoracotomy rate from 5.0% to 1.8% in pa-
tients undergoing heart surgery. When combining the
cost data with the results of the meta-analysis, the ex-
pected average costs per patient treated with aprotinin
(including drug costs) were DM 21,432 compared to DM
21,655 per patient without aprotinin treatment. A cost-
effectiveness analysis (costs per patient without rethora-
cotomy) resulted in a difference of DM 970 in favour of
the prophylactic antihemorrhagic treatment. CONCLU-
SION: The analysis showed that CABG patients requir-
ing an additional rethoracotomy generated about 47%
higher costs than patients with CABG surgery only. The
administration of the antihemorrhagic agent aprotinin
can be recommended in the light of the reduced compli-
cation rate and improved cost-effectiveness of CABG-sur-
gery.
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The use of glycoprotein 2b/3a receptor antagonists has
been shown to be beneficial in elective coronary stent im-
plantation. In Canada, the cost of abciximab has limited
widespread use in this population. Recently presented
data comparing eptifibatide with heparin alone in a simi-
lar population has suggested a significant improvement in
clinical outcomes with this less expensive agent. There
are no trials directly comparing these two agents in the
elective stent patient population. OBJECTIVE: the pur-
pose of this study was to assess the cost-effectiveness of
abciximab or eptifibatide compared to standard therapy
in patients undergoing elective stent placement in a Cana-
dian setting using a decision analysis model. METHODS:
Clinical outcome data was abstracted from the Epistent
and Esprit trials. Economic data assessing direct costs for
coronary intervention procedures and complications was
acquired from the London Health Sciences Centre hospi-
tal cost database for the period 1998–99. The composite
clinical endpoint was freedom from death, myocardial in-
farction and urgent revascularization at 30 days. The pri-
mary study outcome was the incremental cost per event
prevented. RESULTS: In the baseline analysis, both
agents compared favorably with standard therapy. Ab-
ciximab had an incremental cost-effectiveness of $US
10,320 per event prevented. Eptifibatide was less costly
and more effective, hence dominant over standard ther-
apy. The baseline analysis yielded a benefit of 6 events
per 1,000 patients treated in favour of abciximab over
eptifibatide. However the incremental cost per event pre-
vented was $US 125,218, a less favorable value. CON-
CLUSION: The incremental cost-effectiveness of abcix-
imab compared to eptifibatide was sensitive to the cost of
abciximab and to the incidence of myocardial infarctions.
A randomized trial comparing abciximab and eptifi-
batide in elective coronary stent placement is necessary to
better assess this issue.
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OBJECTIVES: Cost-effectiveness studies can provide
valuable information for decision-making processes,
where limited resources need to be allocated across a va-
riety of different treatments. However, it is argued that
the current methods for conducting and reporting cost-
effectiveness results for this purpose are sub-optimal.
This literature review and analysis compares the most re-
cent hypertension cost-effectiveness studies. The goal is
to contribute information so that future cost-effectiveness
studies of hypertension treatments will provide more
optimal information for clinicians and other decision-
makers for the choice of antihypertensive treatment.
METHOD: A literature search of several databases for
the years 1995–2000 was conducted using the following
keywords: hypertension and cost-effectiveness and/or
economics. RESULTS: The search resulted in 89 articles,
of which only 11% (10 studies) were true pharmacoeco-
nomic studies that contained actual data analysis. Of the
10 studies, the majority reported outcome measures in
terms of cost per life year gained, but usually considered
more than one outcome measure. Coronary heart dis-
